Rapport Therapeutics Inc (RAPP)

Oct 11, 2026

Which Brain Pathways Is Rapport Therapeutics Trying to Tune? - Kalkine Media

Oct 11, 2026

Oct 10, 2026

Form 4 Rapport Therapeutics Inc For: 10 October By Investing.com - Investing.com South Africa

Oct 10, 2026

Oct 10, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock - Investing.com

Oct 10, 2026

Oct 10, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock By Investing.com - Investing.com South Africa

Oct 10, 2026

Oct 10, 2026

Form 4 Rapport Therapeutics Inc For: 10 October By Investing.com - Investing.com Canada

Oct 10, 2026

Oct 06, 2026

Form 144 RAPPORT THERAPEUTICS For: 6 October By Investing.com - Investing.com Canada

Oct 06, 2026

Oct 06, 2026

Guggenheim Initiates Rapport Therapeutics at Buy With $65 Price Target - marketscreener.com

Oct 06, 2026

Oct 01, 2026

Form 144 Rapport Therapeutics For: 1 October By Investing.com - Investing.com Nigeria

Oct 01, 2026

Sep 28, 2026

RAPP 10-Q FilingsRapport Therapeutics, Inc. SEC 10-Q - Stock Titan

Sep 28, 2026

Sep 28, 2026

Spyre Therapeutics (SYRE) Stock Price, News & Analysis - Stock Titan

Sep 28, 2026

Sep 25, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com India

Sep 25, 2026

Sep 24, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com Nigeria

Sep 24, 2026

Sep 24, 2026

Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com India

Sep 24, 2026

Sep 24, 2026

Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com Canada

Sep 24, 2026

Sep 24, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com

Sep 24, 2026

Sep 24, 2026

Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com UK

Sep 24, 2026

Sep 24, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com UK

Sep 24, 2026

Sep 24, 2026

RAPP Form 4 FilingsRapport Therapeutics, Inc. SEC Form 4 - Stock Titan

Sep 24, 2026

Sep 23, 2026

Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo Finance

Sep 23, 2026

Sep 23, 2026

Why is Rapport Therapeutics stock sliding today? - Investing.com

Sep 23, 2026

Sep 23, 2026

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research

Sep 23, 2026

Sep 22, 2026

Raymond James reiterates Strong Buy on Rapport Therapeutics stock By Investing.com - Investing.com Nigeria

Sep 22, 2026

Sep 22, 2026

Raymond James reiterates Strong Buy on Rapport Therapeutics stock - Investing.com

Sep 22, 2026

Sep 21, 2026

Rapport Therapeutics (Nasdaq:RAPP)Stock Analysis - simplywall.st

Sep 21, 2026

Sep 16, 2026

Stifel reiterates Rapport Therapeutics stock rating on epilepsy drug outlook - Investing.com

Sep 16, 2026

Sep 15, 2026

Truist reiterates Buy on Rapport Therapeutics stock ahead of data - Investing.com

Sep 15, 2026

Sep 10, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Australia

Sep 10, 2026

Sep 10, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com India

Sep 10, 2026

Sep 10, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $373,980 of common shares - Bitget

Sep 10, 2026

Sep 09, 2026

Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com Canada

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com Nigeria

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com India

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com UK

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Nigeria

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com South Africa

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com South Africa

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock - Investing.com

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Canada

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics Slides As Rally Loses Steam - TipRanks

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics (RAPP) Falls 4% to $44.24: Biotech Pullback Tests Trader PatienceWave Equality - siam.in

Sep 09, 2026

Sep 09, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com UK

Sep 09, 2026

Sep 05, 2026

Why (RAPP) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Sep 05, 2026

Sep 03, 2026

RAPP 8-K FilingsRapport Therapeutics, Inc. SEC 8-K - Stock Titan

Sep 03, 2026

Sep 02, 2026

JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - moomoo.com

Sep 02, 2026

Sep 02, 2026

Rapport Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Sep 02, 2026

Sep 02, 2026

A biotech plans two September talks, one in New York and one online - Stock Titan

Sep 02, 2026

Aug 30, 2026

Rapport Therapeutics (RAPP) Slips 4% as Biotech Pullback Tests Key SupportRisk Reversal - dars.gov.et

Aug 30, 2026

Aug 30, 2026

Rapport Therapeutics (RAPP) Slips 4% as Biotech Pullback Tests Key SupportFast Moving Stocks - vinanet.vn

Aug 30, 2026

Aug 26, 2026

Rapport Therapeutics CEO Abraham Ceesay Sells 18,921 Shares Under Rule 10b5-1 Plan - Kalkine Media

Aug 26, 2026

Aug 25, 2026

Rapport (NASDAQ: RAPP) insider lines up stock sale after August plan trades - Stock Titan

Aug 25, 2026